COVID‐19 pandemic and allergen immunotherapy - an EAACI survey

Simple item page
dc.contributor.authorPfaar, Oliveren
dc.contributor.authorAgache, Ioanaen
dc.contributor.authorBonini, Matteoen
dc.contributor.authorBrough, Helen Annaruthen
dc.contributor.authorChivato, Tomásen
dc.contributor.authorDel Giacco, Stefano R.en
dc.contributor.authorGawlik, Radoslawen
dc.contributor.authorGelincik, Aslıen
dc.contributor.authorHoffmann‐Sommergruber, Karinen
dc.contributor.authorJutel, Mareken
dc.contributor.authorKlimek, Ludgeren
dc.contributor.authorKnol, Edward F.en
dc.contributor.authorLauerma, Anttien
dc.contributor.authorOllert, Markusen
dc.contributor.authorO’Mahony, Liamen
dc.contributor.authorMortz, Charlotte G.en
dc.contributor.authorPalomares, Oscaren
dc.contributor.authorRiggioni, Carmenen
dc.contributor.authorSchwarze, Jürgenen
dc.contributor.authorSkypala, Isabelen
dc.contributor.authorJosé Torres, Maríaen
dc.contributor.authorUntersmayr, Evaen
dc.contributor.authorWalusiak‐Skorupa, Jolantaen
dc.contributor.authorChaker, Adamen
dc.contributor.authorGiovannini, Mattiaen
dc.contributor.authorHeffler, Enricoen
dc.contributor.authorJensen‐Jarolim, Erikaen
dc.contributor.authorQuecchia, Cristinaen
dc.contributor.authorSandoval‐Ruballos, Mónicaen
dc.contributor.authorSahiner, Umiten
dc.contributor.authorTomić Spirić, Vesnaen
dc.contributor.authorAlvaro‐Lozano, Montserraten
dc.date.accessioned2023-12-06T16:34:45Z
dc.date.available2023-12-06T16:34:45Z
dc.date.issued2021-03-02en
dc.description.abstractBackground: As in many fields of medical care, the coronavirus disease 2019 (COVID-19) resulted in an increased uncertainty regarding the safety of allergen immunotherapy (AIT). Therefore, the European Academy of Allergy and Clinical Immunology (EAACI) aimed to analyze the situation in different countries and to systematically collect all information available regarding tolerability and possible amendments in daily practice of sublingual AIT (SLIT), subcutaneous AIT (SCIT) for inhalant allergies and venom AIT. Methods: Under the framework of the EAACI, a panel of experts in the field of AIT coordinated by the Immunotherapy Interest Group set-up a web-based retrospective survey (SurveyMonkey®) including 27 standardized questions on practical and safety aspects on AIT in worldwide clinical routine. Results: 417 respondents providing AIT to their patients in daily routine answered the survey. For patients (without any current symptoms to suspect COVID-19), 60% of the respondents informed of not having initiated SCIT (40% venom AIT, 35% SLIT) whereas for the maintenance phase of AIT, SCIT was performed by 75% of the respondents (74% venom AIT, 89% SLIT). No tolerability concern arises from this preliminary analysis. 16 physicians reported having performed AIT despite (early) symptoms of COVID-19 and/or a positive test result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Conclusions: This first international retrospective survey in atopic diseases investigated practical aspects and tolerability of AIT during the COVID-19 pandemic and gave no concerns regarding reduced tolerability under real-life circumstances. However, the data indicate an undertreatment of AIT, which may be temporary, but could have a long-lasting negative impact on the clinical care of allergic patients.en
dc.description.statusPeer revieweden
dc.description.versionPublished Versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationPfaar, O., Agache, I., Bonini, M., Brough, H. A., Chivato, T., Del Giacco, S. R., Gawlik, R., Gelincik, A., Hoffmann-Sommergruber, K., Jutel, M., Klimek, L., Knol, E. F., Lauerma, A., Ollert, M., O’Mahony, L., Mortz, C. G., Palomares, O., Riggioni, C., Schwarze, J., Skypala, I., Torres, M. J., Untersmayr, E., Walusiak-Skorupa, J., Chaker, A., Giovannini, M., Heffler, E., Jensen-Jarolim, E., Quecchia, C., Sandoval-Ruballos, M., Sahiner, U., Tomić Spirić, V. and Alvaro-Lozano, M. (2021) 'COVID-19 pandemic and allergen immunotherapy - an EAACI survey', Allergy, 76(11), pp. 3504-3516. doi: 10.1111/all.14793https://doi.org/10.1111/all.14793en
dc.identifier.doi10.1111/all.14793en
dc.identifier.eissn1398-9995en
dc.identifier.endpage3516en
dc.identifier.issn0105-4538en
dc.identifier.issued11en
dc.identifier.journaltitleAllergyen
dc.identifier.startpage3504en
dc.identifier.urihttps://hdl.handle.net/10468/15311
dc.identifier.volume76en
dc.language.isoenen
dc.publisherJohn Wiley & Sons, Inc.en
dc.rights© 2021, The Authors. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/en
dc.subjectAllergen immunotherapy (AIT)en
dc.subjectCOVID-19en
dc.subjectPandemicen
dc.subjectSARS-CoV-2en
dc.subjectSurveyen
dc.titleCOVID‐19 pandemic and allergen immunotherapy - an EAACI surveyen
dc.typeArticle (peer-reviewed)en
oaire.citation.issue11en
oaire.citation.volume76en
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Allergy - 2021 - Pfaar - COVID‐19 pandemic and allergen immunotherapy an EAACI survey.pdf
Size:
1.26 MB
Format:
Adobe Portable Document Format
Description:
Published Version
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Microbiology - Journal Articles
APC Microbiome Ireland - Journal Articles
Medicine - Journal Articles